Dr. Chad A. Whyte, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 152
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NE license 26265
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Medical Center Omaha, NE
- Bryan Medical Center Lincoln, NE
Medical groups
- Neurology Consultants of Nebraska PC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 152
- Services billed
- 32,320
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 32,600 | 61 |
| Established patient office or other outpatient visit, 20-29 minutes | 187 | 109 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 163 | 61 |
| Established patient office or other outpatient visit, 30-39 minutes | 126 | 90 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
| Injection of trigger points, 3 or more muscles | 15 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sumatriptan Succinate Other prescribers in Omaha, NE | 285 |
| Gabapentin Other prescribers in Omaha, NE | 160 |
| Naltrexone Hcl Other prescribers in Omaha, NE | 144 |
| Qulipta (atogepant) Other prescribers in Omaha, NE | 126 |
| Aimovig Autoinjector (erenumab-aooe) Other prescribers in Omaha, NE | 119 |
| Rizatriptan (rizatriptan benzoate) Other prescribers in Omaha, NE | 116 |
| Nurtec Odt (rimegepant sulfate) Other prescribers in Omaha, NE | 114 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in Omaha, NE | 103 |
| Topiramate Other prescribers in Omaha, NE | 99 |
| Ubrelvy (ubrogepant) Other prescribers in Omaha, NE | 88 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 309 payments worth $96,723 in total to this clinician.
| AbbVie Inc. | $44,928 |
|---|---|
| Axsome Therapeutics, Inc. | $25,726 |
| Lundbeck LLC | $12,557 |
| Pfizer Inc. | $11,266 |
| Teva Pharmaceuticals USA, Inc. | $324 |
| Novartis Pharmaceuticals Corporation | $262 |
| UCB, Inc. | $248 |
| Neurocrine Biosciences, Inc. | $193 |
| Compensation for services other than consulting (speaking, faculty) | $53,325 |
|---|---|
| Honoraria | $35,152 |
| Food and Beverage | $4,752 |
| Consulting Fee | $2,525 |
| Travel and Lodging | $968 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. Oct 23, 2025 | Honoraria Symbravo · Neurology | $4,025 |
| Axsome Therapeutics, Inc. Jul 17, 2025 | Honoraria Symbravo · Neurology | $4,025 |
| Lundbeck LLC Oct 29, 2025 | Honoraria VYEPTI · NEUROLOGY | $3,500 |
| AbbVie Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| AbbVie Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) UBRELVY · NEUROSCIENCE | $3,250 |
| AbbVie Inc. Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| AbbVie Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| AbbVie Inc. Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $3,250 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
All 38 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. Dec 9, 2025 | Honoraria Symbravo · Neurology | $2,588 |
| AbbVie Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| Pfizer Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,150 |
| Axsome Therapeutics, Inc. Nov 13, 2025 | Honoraria Symbravo · Neurology | $1,725 |
| Pfizer Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,150 |
| Pfizer Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,150 |
| Axsome Therapeutics, Inc. Nov 5, 2025 | Honoraria Symbravo · Neurology | $1,869 |
| Lundbeck LLC Oct 29, 2025 | Honoraria VYEPTI · NEUROLOGY | $3,500 |
| Axsome Therapeutics, Inc. Oct 23, 2025 | Honoraria Symbravo · Neurology | $4,025 |
| Axsome Therapeutics, Inc. Oct 23, 2025 | Honoraria Symbravo · Neurology | $2,588 |
| Axsome Therapeutics, Inc. Oct 23, 2025 | Travel and Lodging Symbravo · Neurology · travel to Oklahoma City, OK · in-kind | $698 |
| Axsome Therapeutics, Inc. Oct 23, 2025 | Travel and Lodging Symbravo · Neurology · travel to Oklahoma City, OK | $117 |
| Axsome Therapeutics, Inc. Oct 23, 2025 | Travel and Lodging Symbravo · Neurology · travel to Oklahoma City, OK | $80.00 |
| Axsome Therapeutics, Inc. Oct 23, 2025 | Travel and Lodging Symbravo · Neurology · travel to Omaha, NE | $48.00 |
| Axsome Therapeutics, Inc. Oct 23, 2025 | Travel and Lodging Symbravo · Neurology · travel to Dallas, TX | $25.36 |
| Lundbeck LLC Sep 30, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $1,000 |
| AbbVie Inc. Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| Pfizer Inc. Sep 25, 2025 | Consulting Fee NURTEC ODT · PAIN | $1,525 |
| Axsome Therapeutics, Inc. Sep 24, 2025 | Honoraria Symbravo · Neurology | $2,588 |
| Axsome Therapeutics, Inc. Sep 18, 2025 | Honoraria Symbravo · Neurology | $1,150 |
| AbbVie Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) UBRELVY · NEUROSCIENCE | $3,250 |
| AbbVie Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| AbbVie Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| AbbVie Inc. Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) UBRELVY · NEUROSCIENCE | $3,250 |
| AbbVie Inc. Aug 18, 2025 | Compensation for services other than consulting (speaking, faculty) UBRELVY · NEUROSCIENCE | $3,250 |
| Axsome Therapeutics, Inc. Aug 14, 2025 | Honoraria Symbravo · Neurology | $1,869 |
| AbbVie Inc. Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $1,625 |
| Lundbeck LLC Aug 5, 2025 | Honoraria VYEPTI · NEUROLOGY | $2,500 |
| Axsome Therapeutics, Inc. Jul 17, 2025 | Honoraria Symbravo · Neurology | $4,025 |
| Lundbeck LLC Jul 15, 2025 | Honoraria VYEPTI · NEUROLOGY | $2,000 |
| Axsome Therapeutics, Inc. Jun 27, 2025 | Honoraria Symbravo · Neurology | $1,725 |
| AbbVie Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $3,250 |
| AbbVie Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $3,250 |
| AbbVie Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $3,250 |
| Lundbeck LLC May 13, 2025 | Honoraria VYEPTI · NEUROLOGY | $3,000 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,250 |
| AbbVie Inc. Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $3,250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 3 companies. The companies reported $382,466 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047444 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - A phase 3 randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of rimegepant in migraine prevention in children and adolescents 6 to 18 years of age
Pfizer Inc. - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie Inc. · Recruiting · NCT06810505 - M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie Inc. - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie Inc. - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
AbbVie Inc. · Enrolling by invitation · NCT05127954 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. · Recruiting · NCT05125302 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie Inc. · Recruiting · NCT05711394
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.